JB Pharma aims to grow its revenue by 12-14% in the next two years

Mumbai-based pharma company JB Pharma is aiming to grow its revenue by 12-14 per cent in the next two years. The company is particularly focused on expanding its presence in the chronic medicines segment and its contract development and manufacturing organisation (CDMO) business. During a recent interaction, JB Pharma CEO Nikhil Chopra highlighted the company's strong performance, attributing the recent surge to a strategic shift towards chronic medications, which offer higher margins. Additionally, Chopra emphasised the significant contribution of the CDMO business, which partners with major players like Procter & Gamble and Johnson & Johnson. Improved profitability in South Africa, which moved from high single digits to mid-teens, has also bolstered overall performance. "We are seeing significant improvements in our chronic business, particularly in cardiology. In three years, we’ve moved from the 13th to the 8th position in this segment. Our cardiology revenue crossed Rs 1,000 crore in 2024, and we continue to touch millions of lives annually," Chopra said. Looking ahead, JB Pharma plans to maintain its presence in cardiology, focusing on hypertension, heart failure, and lipid-lowering treatments. There are ongoing efforts to expand in diuretics, arrhythmias, and blood thinners, potentially through acquisitions or organic growth.